Trials / Recruiting
RecruitingNCT06587061
HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
An Exploratory Clinical Study of HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Detailed description
This study is an open, single center, exploratory clinical trial aimed at evaluating the safety and efficacy of HRS-4642 in combination with gemcitabine and albumin-bound paclitaxel for neoadjuvant and adjuvant treatment of pancreatic cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-4642+AG | HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel will be administrated per dose level in which the patients are assigned. |
Timeline
- Start date
- 2024-12-03
- Primary completion
- 2027-06-01
- Completion
- 2027-12-01
- First posted
- 2024-09-19
- Last updated
- 2025-08-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06587061. Inclusion in this directory is not an endorsement.